Upper GI 2017

Oesophageal Cancer – CROSS Study (I+II)

CROSS I and II study (n=418)

Relapse

After Resection (n=161) n %

After RCTx+ Resection (n=213) n %

HR P-

value

Mediastinum

33

20.5%

15

7.0%

0.29 <0.001

Hematogenous

57

35.4%

61

28.5%

0.67 0.03

Distant disease control is still not optimal with the CROSS regimen

Oppedijk et al. J Clin Oncol 2014; 32:385-391

© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick